WAM
ABUS icon

Weiss Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Weiss Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,800
Closed -$41K – 304
2018
Q4 		$41K Buy
+10,800
New +$53.2K ﹤0.01% 443

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Weiss Asset Management's ABUS Position: Q1 2019 in Review

Weiss Asset Management sold out of Arbutus Biopharma (ABUS) in Q1 2019, closing a stake of 10,800 shares — an estimated $41K sold.

Weiss Asset Management first reported a position in ABUS in Q4 2018 and held it in 1 quarter. The position peaked at $41K in Q4 2018. 72 funds tracked by Wall St. Rank hold ABUS as of Q1 2019.

  • Weiss Asset Management reported no remaining Arbutus Biopharma position as of Q1 2019 after selling out during the quarter.
  • Weiss Asset Management sold 10,800 Arbutus Biopharma shares in Q1 2019, an estimated $41K.
  • Weiss Asset Management first reported a position in Arbutus Biopharma in Q4 2018 and held it in 1 quarter.
  • Weiss Asset Management's Arbutus Biopharma position peaked at $41K in Q4 2018.
  • 72 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2019.

Based on Weiss Asset Management's 13F filing for Q1 2019, filed 15 May 2019.